ADVERTISEMENT
Joshua Bauml, MD, Shares Insight on the 2019 Perspectives in Thoracic Oncology Meeting
Perspectives in Thoracic Oncology, the premiere conference for lung cancer healthcare professionals, has some of the best speakers in the field. One of those speakers, who’s come back year over year to share his knowledge and expertise, is Dr. Joshua Bauml, Assistant Professor of Medicine, Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania.
We sat down with Dr. Bauml recently to discuss his contribution to the meeting:
What lectures will you be participating in this year?
This year I will be speaking about oligometastatic disease in lung cancer, and I will also be participating in a number of panels about the management of patients with tumors harboring rarer molecular alterations.
Can you share a piece of information about the content of the lecture that you think will be most impactful and important for our audience?
In terms of oligometastatic disease, the key thing to remember is that there is now a growing pool of data that indicates that locally ablative therapies can improve outcomes for some patients with oligometastatic lung cancer. How to select those patients, and even how to define oligometastatic disease, is tricky and more research is needed.
What do you love about Perspectives in Thoracic Oncology?
Dr. Langer brings together a fantastic group of faculty year after year and asks the key questions to bring the discussion to the next level. I always learn something new at the Perspectives meeting, and this year I am so excited it has gone bicoastal!
